EP0725838A4 - Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics - Google Patents

Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics

Info

Publication number
EP0725838A4
EP0725838A4 EP94932048A EP94932048A EP0725838A4 EP 0725838 A4 EP0725838 A4 EP 0725838A4 EP 94932048 A EP94932048 A EP 94932048A EP 94932048 A EP94932048 A EP 94932048A EP 0725838 A4 EP0725838 A4 EP 0725838A4
Authority
EP
European Patent Office
Prior art keywords
vaccines
therapeutics
diagnostics
synthetic antigen
structured synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94932048A
Other languages
German (de)
French (fr)
Other versions
EP0725838A1 (en
Inventor
Chang Yi Wang
Timothy J Zamb
John Ye
Stephen M Kaminsky
Barbara Hosein
Douglas F Nixon
C Wayne Koff
Jacek Kowalski
Alan M Walfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Biomedical Inc
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Publication of EP0725838A1 publication Critical patent/EP0725838A1/en
Publication of EP0725838A4 publication Critical patent/EP0725838A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EP94932048A 1993-10-26 1994-10-26 Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics Withdrawn EP0725838A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14341293A 1993-10-26 1993-10-26
US143412 1993-10-26
PCT/US1994/012268 WO1995011998A1 (en) 1993-10-26 1994-10-26 Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics

Publications (2)

Publication Number Publication Date
EP0725838A1 EP0725838A1 (en) 1996-08-14
EP0725838A4 true EP0725838A4 (en) 1997-02-26

Family

ID=22503951

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94932048A Withdrawn EP0725838A4 (en) 1993-10-26 1994-10-26 Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics

Country Status (5)

Country Link
EP (1) EP0725838A4 (en)
AU (1) AU8091694A (en)
CA (1) CA2175579A1 (en)
IL (1) IL111417A0 (en)
WO (1) WO1995011998A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3355095A (en) * 1994-09-02 1996-03-27 Meiji Milk Products Company Limited Diagnostic drug for chlamydia infection
WO1996012186A1 (en) * 1994-10-14 1996-04-25 Chiron Mimotopes Pty. Ltd. Method and apparatus for efficient mimotope discovery
GB2294690B (en) * 1994-11-01 1998-10-28 United Biomedical Inc Peptides effective for diagnosis and detection of hepatitis C infection
JPH11505724A (en) * 1995-06-02 1999-05-25 エム・アンド・イー・バイオテク・エー／エス Methods for identifying biologically active peptides and nucleic acids
DE69621940T2 (en) 1995-08-18 2003-01-16 Morphosys Ag PROTEIN - / (POLY) PEPTIDE LIBRARIES
DE19540105C1 (en) * 1995-09-19 1997-02-20 United Biomedical Inc Compsn. contg. synthetic peptide(s) reactive with hepatitis C related antibodies
AU7247896A (en) * 1995-09-29 1997-04-17 Scripps Research Institute, The Protein signature analysis
AU1707497A (en) 1996-01-23 1997-08-20 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and rna molecules
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
IL121114A (en) * 1997-06-19 2001-03-19 Savyon Diagnostics Ltd C pneumoniae specific peptides and their use in diagnostic assays
IL121115A (en) * 1997-06-19 2001-06-14 Savyon Diagnostics Ltd C. trachomatis specific peptides and their use in diagnostic assays
US6107021A (en) * 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
PT1100922E (en) * 1998-07-31 2008-05-30 Gundersen Lutheran Medical Fou Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
CN1423698A (en) 1999-11-16 2003-06-11 真那特应用生物科技有限公司 The Genome of the HIV-1 inter-subtype (C/B') and use thereof
BR0001717B1 (en) * 2000-05-04 2013-10-08 SYNTHETIC VACCINE FOR TICK CONTROL
FR2809402A1 (en) * 2000-05-26 2001-11-30 Dev Des Antigenes Combinatoire CONVERGENT COMBINATORY PEPTIDE LIBRARIES AND THEIR APPLICATION TO VACCINATION AGAINST HEPATITIS C VIRUS
US6780969B2 (en) 2000-12-22 2004-08-24 United Biomedical, Inc. Synthetic peptide composition as immunogens for prevention of urinary tract infection
EP1229045A1 (en) 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
EP1386927B1 (en) 2002-08-02 2005-03-30 Institut Curie Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors
RU2237065C2 (en) * 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Chimeric peptide immunogenic library mimicking genetic diversity of hypervariable region of protein v3 of human immunodeficiency virus envelope gp120
CA2575218C (en) 2004-07-28 2013-07-09 National Research Council Of Canada Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof
JP2008526186A (en) * 2005-01-03 2008-07-24 エフ．ホフマン−ラ ロシュ アーゲー Hemopexin-like structure as a polypeptide scaffold
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3023436A1 (en) 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
RU2569187C2 (en) 2009-05-29 2015-11-20 МорфоСис АГ Collection and methods of its application
WO2011147975A1 (en) 2010-05-28 2011-12-01 Spixia Biotechnology Ab Chimeric momp antigen, method and use
MX353795B (en) 2010-11-19 2018-01-30 Morphosys Ag A collection and methods for its use.
JP2014527085A (en) * 2011-09-17 2014-10-09 スーチョウ ナアオ ニュー マテリアル サイエンシーズ カンパニー リミテッド Antibody recognizing arbitrarily designed epitope of 3 or more amino acid residues in peptide and method for producing the same
US10660951B2 (en) * 2012-09-17 2020-05-26 Zhiwei Allen Wu Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
CN104244973B (en) 2012-11-16 2017-10-20 美国联合生物医学公司 For the urgent vaccine based on synthetic peptide of aftosa (FMD)
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
CN107073086B (en) 2014-07-25 2021-07-27 美国联合生物医学公司 Immune LHRH composition and application thereof in pigs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009300A1 (en) * 1990-11-21 1992-06-11 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
EP0639584A1 (en) * 1993-06-22 1995-02-22 Interpharm Laboratories Ltd. Preparation and screening of highly diverse peptide libraries for binding activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106726A (en) * 1990-02-16 1992-04-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009300A1 (en) * 1990-11-21 1992-06-11 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
EP0639584A1 (en) * 1993-06-22 1995-02-22 Interpharm Laboratories Ltd. Preparation and screening of highly diverse peptide libraries for binding activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A FURKA ET AL.: "General method for rapid synthesis of multicomponent peptide mixtures", INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, vol. 37, no. 1, January 1991 (1991-01-01), COPENHAGEN DK, pages 487 - 493, XP000206365 *
See also references of WO9511998A1 *

Also Published As

Publication number Publication date
WO1995011998A1 (en) 1995-05-04
CA2175579A1 (en) 1995-05-04
EP0725838A1 (en) 1996-08-14
IL111417A0 (en) 1994-12-29
AU8091694A (en) 1995-05-22

Similar Documents

Publication Publication Date Title
IL111417A0 (en) Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US5669731B1 (en) Component retaining legs
GB9513261D0 (en) Vaccines
IL101690A0 (en) Antibodies and methods utilizing the same
HU9601574D0 (en) Humanized antibodies and uses thereof
ZA947828B (en) Vaccines
EP0660700A4 (en) Method for permanently shaping keratinous materials.
GB9412166D0 (en) Retargetting antibodies
GB9325496D0 (en) Vaccines
IL98769A0 (en) Synthetic peptides,mixtures thereof and methods utilizing the same for detecting hiv antibodies
IL109437A0 (en) 2-Amino-4-quinolyldihydropyridines, processes for their preparation and their use
GB9516293D0 (en) Novel peptides and their use as vaccines
IL123153A0 (en) Antigenic preparations
ZA9610102B (en) Salmonella vaccines.
EP0456727A4 (en) Monoclonal antibodies directed against vitronectin and fibronectin, and uses thereof
DE69513047T2 (en) BACKREST
ZA948685B (en) Vaccines
ZA947661B (en) Vaccines and diagnostics.
EP0681480A4 (en) Recognin vaccines.
GB2267148B (en) Footrot antigens,vaccines and diagnostic assays
ZA939564B (en) Vaccines.
GB2314560B (en) Synthetic peptides of m. gallisepticum, antibodies thereto, their preparations and use
GB9503867D0 (en) Vaccines and diagnostics
IL104767A0 (en) Antigenic epitopes and antibodies against them
ZA922978B (en) Novel antibodies and methods for their use.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960424

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970107

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19970401

R18W Application withdrawn (corrected)

Effective date: 19970403